Notable progress in biological therapies has underscored that the interplay of interleukin (IL)-23p19, the IL-17A signaling axis, and tumor necrosis factor-alpha (TNF-α) is fundamental in the context of inflammatory diseases, along with the participation of skin-resident immune cells and essential signaling pathways in the pathogenesis of psoriasis. Here, IL23A is linked to psoriasis.